Related Experiment Videos
Imatinib and spironolactone suppress hepcidin expression
Katarzyna Mleczko-Sanecka1,2, Ana Rita da Silva3, Debora Call3
1Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg and Molecular Medicine Partnership Unit, Heidelberg, Germany martina.muckenthaler@med.uni-heidelberg.de kmsanecka@iimcb.gov.pl.
Haematologica
|April 8, 2017
Summary
Certain medications, like spironolactone and imatinib, can alter hepcidin levels, impacting iron homeostasis. This finding may inform patient management and reveal potential drug side effects related to iron metabolism.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Background:
- Hepcidin is the master regulator of systemic iron homeostasis.
- Disorders of iron metabolism often stem from abnormal hepcidin expression.
Purpose of the Study:
- To investigate if drugs targeting genetic hepcidin regulators can modulate iron homeostasis.
- To identify approved drugs for repositioning or to reveal iron-related side effects.
Main Methods:
- Re-evaluation of a genome-wide RNAi screen for hepcidin regulators.
- Validation using RNAi, small-molecule testing in cell lines, primary hepatocytes, and mice.
- Identification and testing of 'druggable' screening hits.
Main Results:
- Spironolactone, diclofenac, imatinib, and SAHA were identified as hepcidin-modulating drugs in cellular assays.
- Imatinib and spironolactone suppressed liver hepcidin expression in mice.
- Spironolactone (anti-hypertensive) and imatinib (cancer therapeutic) were confirmed to suppress hepcidin expression.
Conclusions:
- Approved drugs, including spironolactone and imatinib, can modulate hepcidin expression.
- These findings have implications for patient management and understanding drug side effects.
- Prospective clinical studies are needed to further address these results.